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Abstract
Neurodegenerative diseases are characterized by the accumulation of specific phosphorylated protein aggregates
in the brain, such as hyperphosphorylated tau (hp-tau) in tauopathies and phosphorylated α-synuclein (p-αSyn) in
α-synucleinopathies. The simultaneous accumulation of different proteins is a common event in many
neurodegenerative diseases. We herein describe the detection of the phosphorylation and dimerization of αSyn
and activation of GSK-3β, a major kinase known to phosphorylate tau and αSyn, in the brains of rTg4510 mice
that overexpress human P301L mutant tau. Immunohistochemistry showed p-αSyn aggregates in rTg4510 mice,
which were suppressed by doxycycline-mediated decreases in mutant tau expression levels. A semi-quantitative
analysis revealed a regional correlation between hp-tau and p-αSyn accumulation in rTg4510 mice. Furthermore,
proteinase K-resistant αSyn aggregates were found in the region with excessive hp-tau accumulation in rTg4510
mice, and these aggregates were morphologically different from proteinase K-susceptible p-αSyn aggregates.
Western blotting revealed decreases in p-αSyn monomers in TBS- and sarkosyl-soluble fractions and increases in
ubiquitinated p-αSyn dimers in sarkosyl-soluble and insoluble fractions in rTg4510 mice. Furthermore, an
activated form of GSK-3β was immunohistochemically detected within cells containing both hp-tau and p-αSyn
aggregates. A semi-quantitative analysis revealed that increased GSK-3β activity strongly correlated with hp-tau
and p-αSyn accumulation in rTg4510 mice. Collectively, the present results suggest that the overexpression of
human P301L mutant tau promoted the phosphorylation and dimerization of endogenous αSyn by activating
GSK-3β in rTg4510 mice. This synergic effect between tau, αSyn, and GSK-3β may be involved in the
pathophysiology of several neurodegenerative diseases that show the accumulation of both tau and αSyn.
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Introduction
The accumulation of specific phosphorylated protein ag-
gregates and neuronal loss in the central nervous system
are hallmarks of several neurodegenerative diseases. The
current pathological classification of neurodegenerative
diseases is based on the proteins that accumulate.
Intracytoplasmic hyperphosphorylated tau (hp-tau) ag-
gregates are pathognomonic in tauopathies such as Alz-
heimer’s disease (AD), frontotemporal dementia with
Parkinsonism linked to chromosome 17 (FTDP-17), and
progressive supranuclear palsy (PSP), while phosphory-
lated α-synuclein (p-αSyn) aggregates are involved in α-
synucleinopathies including Parkinson’s disease (PD),
dementia with Lewy bodies (DLB), and multiple system
atrophy (MSA) [50].
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Tau and αSyn are both natively unfolded soluble pro-
teins that are minimally phosphorylated in the normal
adult brain. However, they undergo conformational
changes, such as phosphorylation, in pathological states,
which subsequently leads to oligomerization. They may
also become ubiquitinated and form intracytoplasmic in-
soluble filamentous aggregates [30, 57]. In AD, tau pro-
teins are hyperphosphorylated at various sites and form
ultrastructural paired helical filaments (PHFs), resulting
in neurofibrillary tangles (NFTs) [1]. Recent data has
brought the total number of identified phosphorylation
sites on tau from AD brain to 45, which represents more
than half of the total of 85 phosphorylatable residues in
tau. Though attempts to identify AD-specific phosphor-
ylation sites on tau have yet to yield conclusive results,
anti-hp-tau antibodies, which recognize tau phosphory-
lated at specific sites such as serine 199, 202, and 396
and threonine 205 positions, are widely used to detect
AD pathology [19]. In α-synucleinopathies, αSyn pro-
teins are mainly phosphorylated at the serine 129 pos-
ition and form intracytoplasmic inclusions called Lewy
bodies (LBs) [2]. The phosphorylation of tau and αSyn is
controlled by several kinases and phosphatases [33, 57].
Glycogen synthase kinase-3β (GSK-3β) and protein
phosphatase-2A (PP2A) are involved in the phosphoryl-
ation processes of both tau and αSyn [1, 10]. Postmor-
tem studies on AD and PD brains revealed the
overactivation of GSK-3β and inactivation of PP2A [10,
27, 55]. The levels of polo-like kinase 2 (PLK2), a major
phosphorylation enzyme for αSyn, but not for tau, were
found to be elevated in the brains of AD patients [35].
Recent studies proposed a seeding hypothesis in which
small amounts of misfolded proteins act as seeds that
initiate the recruitment of their soluble counterparts into
fibrils and the cell-to-cell transmission of protein aggre-
gates [30, 34]. The spread of hp-tau and p-αSyn accu-
mulation closely correlates with disease progression;
therefore, the distribution of hp-tau and p-αSyn is im-
portant for identifying the disease stages of sporadic AD
and PD, respectively [30, 46]. Furthermore, an oligomer
hypothesis has been proposed in α-synucleinopathies
[43]. Under normal conditions, αSyn molecules are un-
folded soluble monomers or tetramers [3], but in patho-
logical states these molecules are phosphorylated, have a
propensity for folding and forming insoluble oligomers,
and through protofibrils become mature fibrils, the main
component of LBs [29]. Accumulating evidence suggests
that the toxic form of αSyn is oligomers, rather than ma-
ture fibrils, which induce neuronal dysfunction and cell
death [12].
The co-deposition of different pathological protein ag-
gregates is common in the brains of individuals with
neurodegenerative diseases [31, 39, 50]. Intracellular p-
αSyn aggregates are frequently found together with hp-
tau accumulation in tauopathies such as AD [24], PSP
[54], and FTD [58]. Studies using antibodies against
αSyn detected LBs in the amygdala of more than 60% of
familial and sporadic AD cases [32]. Conversely, hp-tau
aggregates have been found in more than 50% of α-
synucleinopathy cases, including cases of PD, DLB, and
MSA [20]. Clinical and postmortem studies revealed that
cases of AD with LBs were associated with faster and
more severe cognitive decline as well as accelerated mor-
tality than AD cases without LBs [28, 42]. Filamentous
aggregates composed of one protein (tau or αSyn) in the
brain have also been suggested to directly promote the
aggregation of other proteins through a process called
cross-seeding [17, 31].
We recently detected p-αSyn aggregates in a tauopathy
mouse model (rTg4510 mice) that overexpresses human
P301L mutant tau, and the accumulation of hp-tau and
p-αSyn increased in an age-dependent manner [52]. In
the present study, we examined the relationship between
the accumulation of hp-tau and p-αSyn in rTg4510 mice
by suppressing the expression levels of mutant tau using
doxycycline. The results obtained suggested that the ac-
cumulation of p-αSyn in rTg4510 mice was dependent
on the extent of hp-tau accumulation. We also revealed
decreases in p-αSyn monomers in TBS- and sarkosyl-
soluble fractions and increases in ubiquitinated p-αSyn
dimers in sarkosyl-soluble and insoluble fractions, and
the activation of GSK-3β in rTg4510 mice. We herein
report the pathological findings of α-synucleinopathy in
the brains of rTg4510 mice and discuss the relationship
between hp-tau and p-αSyn accumulation.
Materials and methods
Animals
A transgenic model for human tauopathy, rTg4510 mice,
and control FVB/N-C57BL/6 J mice were used (https://
www.alzforum.org/research-models/rtgtaup301l4510).
These transgenic mice overexpress human tau, which
contains the frontotemporal dementia-associated P301L
mutation; tau expression may be suppressed by doxycyc-
line. Regarding the expression of mutant tau in rTg4510
mice, the mutated gene, which is located downstream of
a tetracycline-operon-responsive element, must be co-
expressed with an activator transgene, which consists of
the tet-off open reading frame located downstream of
Ca2+-calmodulin kinase II promoter elements, resulting
in human P301L tau overexpression restricted to fore-
brain structures, which characterized with tau pathology
in the form of argyrophilic tangle-like inclusions in the
cerebral cortex and hippocampus, and behavioral im-
pairments by 3 months of age [49].
rTg4510 mice (transgenic for both a tau responder
transgene and an activator transgene) and littermate
wild-type control mice that do not express tau (lacking
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either the tau responder transgene or the activator trans-
gene) were maintained in an experimental facility at the
University of Tokyo. Mice were housed in a cage with
free access to a standard diet (MS food, Oriental Yeast,
Tokyo, Japan). To suppress CamkIIa-tTA-driven human
tau transgene expression, rTg4510 mice were fed a diet
containing 200 mg/kg doxycycline (5TP7, TestDiet, St.
Louis, MO) ad libitum from 2.5 to 10 months of age
(n = 10). The remaining mice were fed a standard diet
without doxycycline (rTg4510, n = 11; wild-type control,
n = 11). Transgenic mice were euthanized at 10 months
of age, and the brains were collected. Experiments were
approved by the Institutional Animal Care and Use
Committee of the Graduate School of Agricultural and
Life Science at the University of Tokyo (Approval No.
L18–042).
Histopathology
Brain tissue samples from the cerebrum and cerebellum
were fixed in 10% neutral-buffered formalin, routinely
processed, and embedded in paraffin wax. Formalin-
fixed and paraffin-embedded tissues were cut into 2- or
8 μm-thick serial sections. Deparaffinized sections were
then stained with hematoxylin and eosin (HE).
Immunohistochemistry
Consecutive sections were stained using an immunoen-
zyme technique. After deparaffinization and rehydration,
antigen retrieval was performed via heating to detect hp-
tau, αSyn, GSK-3β, and p-GSK-3β (Tyr216). A formic
acid treatment was used to detect p-αSyn. To deactivate
endogenous peroxidase, sections were immersed in 1%
hydrogen peroxide in methanol for 5 min. To avoid non-
specific binding of the antibody, sections were immersed
in 8% skim milk in Tris-buffered saline (TBS). The fol-
lowing primary antibodies were used: mouse anti-hp-tau
(clone AT8, 1:500, Thermo Scientific, Rockford, IL),
rabbit anti-αSyn (clone D37A6, 1:500, Cell Signaling
Technology, Beverly, MA), rabbit anti-GSK-3β (clone
27C10, 1:100, Cell Signaling Technology), rabbit anti-p-
GSK-3β (Tyr216) (1:100, Novus Biologicals, Centennial,
CO), rabbit anti-p-αSyn (clone D1R1R, 1:500, Cell
Signaling Technology), mouse anti-p-αSyn (clone 81A,
1:500, Abcam, Cambridge, UK), and rabbit anti-p-αSyn
(clone EP1536Y, 1:500, Abcam). After an incubation
with each primary antibody at 4 °C overnight, immuno-
labeled antigens were visualized using the Dako EnVi-
sion+ System (Dako, Glostrup, Denmark) with 0.02% 3′
3-diaminobenzidine plus 0.01% hydrogen peroxide as a
chromogen. For semiquantitative analysis, we used
rTg4510 mice fed the standard (n = 11) or doxycycline
diet (n = 10). To evaluate hp-tau and p-αSyn deposition
and the activation of GSK-3β, the numbers of hp-tau
(clone AT8)-, p-αSyn (clone D1R1R)-, and p-GSK-3β
(Tyr216)-positive cells were counted, respectively. We
counted the number of cells with intracytoplasmic grains
that were stained positive with each of the antibodies. In
each region, we counted three different areas (0.14mm2
each), and the average was used for the number of posi-
tive cells in the region of the mice.
Proteinase K digestion
To detect proteinase K-resistant αSyn, after antigen re-
trieval, sections were treated with 50 μg/ml proteinase K
(Wako, Osaka, Japan) in Tris HCl buffer containing 10
mM Tris-HCl (pH 7.8), 100 mM NaCl, and 0.1%
Nonidet-P40 at 37 °C for 3 min. Sections were then sub-
jected to immunohistochemical processing using a rabbit
anti-αSyn antibody (clone D37A6, 1:500).
Double-labeling immunofluorescence
To detect the spatial and temporal distribution of hp-
tau, p-αSyn, and p-GSK-3β (Tyr216), we performed
double-labeling immunofluorescence. After an incuba-
tion with each of the primary antibodies at 4 °C over-
night, sections were washed with TBS, incubated with
the corresponding secondary antibody at room
temperature for 1 h, and then mounted with Vectashield
(H-1500, Vector Laboratories, Burlingame, CA). The fol-
lowing primary antibodies were used: mouse anti-hp-tau
(clone AT8, 1:100), mouse anti-p-αSyn (clone 81A, 1:
100), and rabbit anti-p-GSK-3β (Tyr216) (1:100). The
following secondary antibodies were used: Alexa Fluor
594-conjugated goat anti-mouse IgG (1:100, Invitrogen,
Eugene, OR), Alexa Fluor 488-conjugated goat anti-
rabbit IgG (1:100, Life Technologies, Eugene, OR), Alexa
Fluor 594-conjugated goat anti-rabbit IgG (1:100, Life
Technologies), and Alexa Fluor 488-conjugated goat
anti-mouse IgG (1:100, Invitrogen). Fluorescent reaction
products were optimally visualized using an argon ion
laser in a Carl Zeiss LSM700 Confocal Laser Scanning
Microscope (Carl Zeiss, Tokyo, Japan).
Protein extraction
Regarding Western blotting, tissue samples from the
hindbrain were homogenized in 7.5 volumes of TBS buf-
fer containing 50 mM Tris (pH 7.4), 150 mM NaCl, 1
mM EGTA, and 1mM EDTA. After centrifugation at
23,000 rpm at 4 °C for 15 min, supernatants were col-
lected as TBS-soluble fractions. Pellets were rehomogen-
ized in 7.5 volumes of sucrose buffer containing 0.32M
sucrose, 10 mM Tris/HCl (pH 7.4), 1 mM EGTA, and
0.8M NaCl and centrifuged as described above. Super-
natants were collected and incubated with sarkosyl
(Wako, 1% final concentration) at 37 °C for 1 h, followed
by centrifugation at 60,000 rpm at 4 °C for 30 min, and
then collected as sarkosyl-soluble fractions. Pellets were
resuspended in TBS buffer to a volume equivalent to the
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wet weight of the original tissue (sarkosyl-insoluble
fractions).
Western blotting
Protein samples were dissolved in Laemmli Sample
Buffer (SB), which included 2-mercaptoethanol, and
were then boiled for 10 min. Proteins dissolved in
Laemmli SB were separated using a 5–20% gradient
polyacrylamide gel (ATTO, Tokyo, Japan) and then
transferred to a nitrocellulose membrane with a pore
size of 0.20 μm (GE Healthcare Bio-Sciences AB, Upp-
sala, Sweden). Non-specific binding was blocked by a
treatment with 1% skim milk for 60 min or Blocking
One P (Nacalai Tesque, Kyoto, Japan) for 3 h. Mem-
branes were probed with the following antibodies at
4 °C overnight: mouse anti-hp-tau (clone AT8, 1:500),
rabbit anti-p-αSyn (clone D1R1R, 1:500), rabbit anti-
GSK-3β (clone 27C10, 1:1000), rabbit anti-p-GSK-3β
(Tyr216) (1:500), rabbit anti-PLK2 (1:500, Thermo
Fisher Scientific, Waltham, MA), rabbit anti-PP2A-C
(1:1000, Cell Signaling Technology), rabbit anti-p-
PP2A-C (Tyr307) (clone F8, 1:500, Santa Cruz Bio-
technology, Dallas, TX), and horseradish peroxidase
(HRP)-conjugated mouse anti-β-actin (clone
8H10D10, 1:5000, Cell Signaling Technology). After
washing the membranes with TBS containing Tween
20, a HRP-conjugated sheep anti-rabbit IgG antibody
(1:5000, GE Healthcare UK, Little Chalfont, UK) or
HRP-conjugated sheep anti-mouse IgG antibody (1:
5000 GE Healthcare UK) was applied. Blots were de-
veloped using ECL Select Western Blotting Detection
Reagent (GE Healthcare Bio-Sciences AB). Immunore-
active bands were detected using the ChemiDoc
XRS+ System (Bio-Rad Laboratories, Hercules, CA).
Statistical analysis
Data are shown as the mean ± standard deviation (SD).
Comparisons of means between rTg4510 and control
mice were performed using a one-way analysis of vari-
ance (ANOVA) followed by Tukey’s multiple compari-
son tests. Relationships between the amounts of hp-tau
and p-αSyn that accumulated and activation of GSK-3β
were examined using Spearman’s rank correlation. A p
value < 0.05 was considered to be significant.
Results
Decreased hp-tau and p-αSyn deposition in doxycycline-
treated rTg4510 mice
We previously reported age-dependent increases in hp-
tau and p-αSyn deposition in rTg4510 mice [52]. In the
present study, the deposition of hp-tau and p-αSyn in
doxycycline-treated rTg4510 mice was examined.
rTg4510 mice fed the standard or doxycycline diet de-
veloped hp-tau aggregates in the neuronal cytoplasm
and neurites of the cerebrum (Fig. 1a, b, Supplementary
Fig. 1). Mice also developed p-αSyn-positive aggregates
in the hippocampal CA1 and CA3 areas, dentate gyrus,
motor area, somatosensory area, entorhinal cortex, piri-
form cortex, and amygdala (Fig. 1d, e, g, h, j, k, Supple-
mentary Fig. 1), which corresponded to the distribution
of hp-tau aggregates. However, there were no hp-tau or
p-αSyn aggregates in the brains of control mice (Fig. 1c,
f, i, l). To elucidate the relationship between the distri-
bution of hp-tau and p-αSyn, we examined the amounts
of hp-tau and p-αSyn that accumulated in 10 regions in
rTg4510 mice fed the standard or doxycycline diet using
immunohistochemistry: the hippocampal CA1 and CA3
areas, dentate gyrus, motor area, somatosensory area,
entorhinal cortex, piriform cortex, amygdala, striatum,
and substantia nigra. rTg4510 mice fed the doxycycline
diet showed a significant decrease of hp-tau and p-αSyn
deposition in the hippocampal CA1 and CA3 areas,
motor area, somatosensory area, entorhinal cortex, piri-
form cortex, amygdala, and striatum, as compared to
rTg4510 mice fed the standard diet (Fig. 2a, b). How-
ever, in the dentate gyrus and substantia nigra, where
few hp-tau inclusions were observed, p-αSyn aggregates
were scarce in rTg4510 mice fed the standard and doxy-
cycline diet. As shown in the scatterplots, a positive
correlation was found between the average amounts of
hp-tau and p-αSyn that accumulated in each region (r =
0.85, p < 0.01) (Fig. 2c). Furthermore, positive correla-
tions were observed between the amounts of hp-tau and
p-αSyn that accumulated in each area (hippocampal
CA1, r = 0.80, p < 0.01; hippocampal CA3, r = 0.94, p <
0.01; motor cortex, r = 0.74, p < 0.01; entorhinal cortex,
r = 0.77, p < 0.01; piriform cortex, r = 0.88, p < 0.01;
amygdala, r = 0.86, p < 0.01) (Fig. 2d-i). There was no
amyloid β pathology in the brains of any mice (data not
shown).
Detection of proteinase K-resistant αSyn in rTg4510 mice
To evaluate the proteinase K resistance of αSyn in
rTg4510 mice, we performed immunohistochemistry for
αSyn after proteinase K digestion. The immunoreactivity
of endogenous αSyn in neuronal cells and neuropils was
negligible in control mice after this treatment, whereas a
few αSyn-positive dense, uniform aggregates were de-
tected in the neuronal cytoplasm of rTg4510 mice
(Fig. 3). These aggregates were found in the hippocam-
pus, motor area, entorhinal cortex, piriform cortex and
amygdala, in which excessive hp-tau and p-αSyn accu-
mulation was observed, in rTg4510 mice (Supplementary
Fig. 2). These aggregates were not detected without pro-
teinase K digestion, and proteinase K-resistant αSyn-
positive aggregates were morphologically different from
p-αSyn-positive aggregates.
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Decreases in p-αSyn monomers and increases in
ubiquitinated p-αSyn dimers in rTg4510 mice
To detect αSyn oligomerization in the brain, protein
samples in TBS-soluble, sarkosyl-soluble, and sarkosyl-
insoluble fractions were examined by Western blotting.
In each fraction, hp-tau-positive bands were detected in
rTg4510 mice (Fig. 4a-c, Supplementary Fig. 4). In TBS-
soluble fractions from rTg4510 and control mice, a p-
αSyn-positive single band, corresponding to the mono-
meric form of αSyn, and a ubiquitin-positive single band,
corresponding to the molecular weight of ubiquitin,
were detected (Fig. 4d, g). The expression levels of the
p-αSyn monomer were significantly lower in rTg4510
mice than in control mice (Fig. 4d). In sarkosyl-soluble
fractions from rTg4510 and control mice, several bands
corresponding to the monomeric and oligomeric forms
of p-αSyn and several ubiquitin-positive bands corre-
sponding to ubiquitin and ubiquitinated proteins were
detected (Fig. 4e, h, Supplementary Fig. 5). The
expression levels of the p-αSyn monomer were signifi-
cantly lower in rTg4510 mice than in control mice (Fig.
4e). Furthermore, the expression levels of p-αSyn with a
molecular weight of approximately 45 kDa were signifi-
cantly higher in rTg4510 mice than in control mice. This
45 kDa band was also positive for ubiquitin, indicating
ubiquitinated p-αSyn dimers (Fig. 4e, h). In sarkosyl-
insoluble fractions from rTg4510 and control mice, sev-
eral p-αSyn-positive bands, corresponding to the mono-
meric and oligomeric forms of αSyn were detected (Fig.
4f). Furthermore, in rTg4510 mice two distinct p-αSyn-
positive bands were detected, approximately 30 and 45
kDa, indicating p-αSyn dimers and ubiquitinated p-αSyn
dimers, respectively (Fig. 4f).
αSyn phosphorylation enzyme in rTg4510 mice
The phosphorylation of αSyn is determined by the bal-
ance between the activities of kinases and phosphatases.
To elucidate the mechanisms underlying changes in
Fig. 1 Immunohistochemistry for hp-tau and p-αSyn in the amygdala of rTg4510 mice fed the standard or doxycycline diet and control mice.
rTg4510 mice developed numerous hp-tau-positive aggregates stained with the anti-hp-tau antibody AT8 (a, b), while control mice did not (c).
rTg4510 mice also developed numerous, p-αSyn-positive aggregates stained with the anti-p-αSyn antibody D1R1R (d, e), 81A (g, h), and EP1536Y
(j, k), while control mice did not (f, i, l). Scale bar: 20 μm (a-l)
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Fig. 2 Semi-quantitative analysis of hp-tau and p-αSyn accumulation in 10 regions: the hippocampal CA1 and CA3 areas, dentate gyrus (DG),
motor area (MO), somatosensory area (SO), entorhinal cortex (ENT), piriform cortex (PIR), amygdala (AMY), striatum (STR), and substantia nigra (SN),
in rTg4510 mice fed the standard (n = 11) or doxycycline (dox) diet (n = 10). The accumulation of hp-tau was decreased in all regions studied in
rTg4510 mice fed the dox diet (*p < 0.01, a The accumulation of hp-tau was decreased in CA1, CA3, MO, SO, ENT, PIR, AMY, and STR in rTg4510
mice fed the dox diet (*p < 0.01, b). Positive correlations were observed between the average accumulation of hp-tau and p-αSyn in each region
(r = 0.85, p < 0.01, c), and between hp-tau and p-αSyn accumulation in CA1 (r = 0.80, p < 0.01, d), CA3(r = 0.94, p < 0.01, e), MO (r = 0.74, p < 0.01, f),
ENT (r = 0.77, p < 0.01, g), PIR (r = 0.88, p < 0.01, h), and AMY (r = 0.86, p < 0.01, i) in rTg4510 mice. Colors: red, CA1; purple, CA3; deep red, DG; pink,
MO; gray; SO; black, ENT; green; PIR; blue, AMY; light blue, STR; orange, SN. Diagrams: circular dot, rTg4510 mice fed the control diet; circle,
rTg4510 mice fed the dox diet
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αSyn phosphorylation in rTg4510 mice, the levels of the
major αSyn kinases (GSK-3β and PLK2) and phosphat-
ase (PP2A) were quantified by Western blotting. No sig-
nificant changes were observed in GSK-3β levels in
rTg4510 mice (Fig. 5a). Western blotting for GSK-3β
phosphorylated at Tyr216 (p-GSK-3β (Tyr216)), an acti-
vated form of GSK-3β, detected two distinct bands with
molecular weights of approximately 46 kDa, correspond-
ing to GSK-3β, and 48 kDa, corresponding to GSK-3α.
The expression levels of p-GSK-3β (Tyr216) were higher
in rTg4510 mice than in control mice (Fig. 5b). No sig-
nificant differences were observed in the levels of PLK2,
PP2A, or PP2A phosphorylated at Tyr307 (p-PP2A
(Tyr307)), an inactivated form of PP2A, between
rTg4510 mice and control mice (Fig. 5c-e).
Spatial and temporal activation of GSK-3β in rTg4510
mice
The immunohistochemical analysis revealed uniform
GSK-3β expression in the neuronal cytoplasm of both
rTg4510 and control mice, and GSK-3β-positive grains
were also found in rTg4510 mice, but not in control
mice (Fig. 6a, c). Furthermore, rTg4510 mice developed
p-GSK-3β (Tyr216)-positive grains in the hippocampal
CA1 and CA3 areas, motor area, somatosensory area,
entorhinal cortex, piriform cortex, amygdala, and stri-
atum, which corresponded to the distribution of hp-tau
and p-αSyn aggregates in rTg4510 mice, but not in
control mice (Fig. 6b, d, Supplementary Fig. 3). A
double-labeling immunofluorescence analysis revealed
that p-GSK-3β (Tyr216)-positive grains and hp-tau and
p-αSyn aggregates were detected within the same cells
(Fig. 6e, f). Moreover, p-αSyn aggregates were only ob-
served in cells with hp-tau aggregates and p-GSK-3β
(Tyr216)-positive grains, and p-GSK-3β (Tyr216)-posi-
tive grains were only detected in cells with hp-tau ag-
gregates. Furthermore, the majority of p-GSK-3β
(Tyr216)-positive grains did not co-localize with hp-tau
aggregates (Fig. 6e), while most p-αSyn aggregates co-
localized with p-GSK-3β (Tyr216)-positive grains (Fig.
6f).
Distribution of activated GSK-3β in rTg4510 mice
To evaluate the relationship between the distribution of
activated GSK-3β and hp-tau or p-αSyn deposition, we ex-
amined the number of p-GSK-3β (Tyr216)-positive cells
using immunohistochemistry in rTg4510 mice fed the
standard or doxycycline diet. Numerous p-GSK-3β
(Tyr216)-positive cells were found in the hippocampal
CA1 area, motor area, somatosensory area, entorhinal
cortex, piriform cortex, amygdala, and striatum, in which
hp-tau and p-αSyn accumulation was excessive (Fig. 7a).
However, few p-GSK-3β (Tyr216)-positive cells were ob-
served in the dentate gyrus and substantia nigra. As shown
in the scatterplots, positive correlations were observed be-
tween the number of hp-tau-positive cells and p-GSK-3β
(Tyr216)-positive cells (r = 0.91, p < 0.01), and between the
average number of hp-tau-positive cells and p-GSK-3β
(Tyr216)-positive cells in each area (r = 0.95, p < 0.01) (Fig.
7b, c). Furthermore, positive correlations were noted be-
tween the number of p-GSK-3β (Tyr216)-positive cells
and p-αSyn-positive cells (r = 0.84, p < 0.01) and between
the average number of p-GSK-3β (Tyr216)-positive cells
and p-αSyn-positive cells in each area (r = 0.93, p < 0.01)
(Fig. 7d, e).
Discussion
We previously reported that rTg4510 mice developed
not only hp-tau aggregates, but also p-αSyn aggregates
in their brains, and the accumulation of both of these
proteins increased in an age-dependent manner [52].
We also detected hp-tau and p-αSyn aggregates in aged
rTg4510 mice fed a doxycycline diet, and confirmed that
the accumulation of p-αSyn in rTg4510 mice treated
with doxycycline, which reduced pathological tau levels,
was less than that in untreated rTg4510 mice. Tau accu-
mulation, even at a very low concentration, results in the
co-accumulation of αSyn polymers in vitro, and this is
Fig. 3 Immunohistochemistry for αSyn with the proteinase K treatment in the motor area of rTg4510 mice and control mice. The proteinase K
treatment diminished neuropil staining in control mice (a, b) and rTg4510 mice (c, d), and a few proteinase K-resistant αSyn aggregates were
found in rTg4510 mice (d). Scale bar: 20 μm (a-d)
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Fig. 4 (See legend on next page.)
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strongly enhanced in a concentration-dependent manner
[15]. Furthermore, the co-expression of tau with αSyn leads
to small αSyn aggregates with enhanced toxicity, which
drives dendritic and synaptic damage in vitro [15]. In
addition to rTg4510 mice, the accumulation of αSyn has also
been found in DLB-AD transgenic mice, which express hu-
man mutant APP, PSEN1, tau (P301L), and αSyn (A53T)
[5], and in bigenic mice that express wild-type human αSyn
and mutant tau (P301L) [15]. In rTg4510 mice, transgene
suppression with doxycycline was shown to lower tau pro-
duction by 85% from untreated levels [48] and reduce neur-
onal death and neuroinflammation [8]. In the present study,
positive correlations were observed between hp-tau and p-
αSyn accumulation in all regions studied in rTg4510 mice
fed the control and doxycycline diets. Therefore, the present
results suggest that hp-tau promotes αSyn phosphorylation
and accumulation in rTg4510 mice, and the accumulation of
hp-tau increases that of p-αSyn in a load-dependent manner
in vivo.
Proteinase K resistance is a salient feature of the mis-
folded proteins relevant to prion diseases [11]. Addition-
ally, proteinase K-resistant αSyn aggregates are found in
human α-synucleinopathies, and proteinase K treatments
are useful for detecting the cytoplasmic and neuritic
pathologies of these patients [14, 38]. Furthermore, ag-
gregated αSyn in the LBs and neurites of PD and DLB
are phosphorylated [37]. In the present study, we de-
tected a few proteinase K-resistant αSyn-positive dense,
uniform aggregates in areas with excessive hp-tau accu-
mulation in rTg4510 mice, and these were morphologic-
ally different from p-αSyn granular deposits. Some α-
synucleinopathy model mice, such as A53T and A30P
αSyn transgenic mice, show the deposition of proteinase
K-resistant αSyn [37, 53]. A53T αSyn transgenic mice
developed proteinase K-resistant αSyn deposits in the
presynapses. These deposits were composed of non-
phosphorylated αSyn, while cytoplasmic phosphorylated
LB-like inclusions were not resistant to proteinase K
(See figure on previous page.)
Fig. 4 Western blotting analysis for hp-tau (AT8), p-αSyn (D1R1R) and ubiquitin in the TBS-soluble, sarkosyl-soluble, and sarkosyl-insoluble fractions
from the hindbrain of rTg4510 mice (Tg) and control mice (WT) (n = 10 for TBS- and sarkosyl soluble fractions of Tg and WT mice, n = 3 for sarkosyl
insoluble fractions of Tg and WT mice). A distinct band of hp-tau with a molecular weight of 50 kDa was detected in the TBS-soluble and sarkosyl-
soluble fractions of Tg brains (a, b), and hp-tau was also detected in the sarkosyl-insoluble fractions of Tg brains (c). A single distinct band of p-αSyn
monomers with a molecular weight of 17 kDa was detected in both mouse brains, and p-αSyn monomers were decreased in Tg brains (*p < 0.01, d).
Additionally, p-αSyn oligomers were detected in the sarkosyl-soluble fractions of both mouse brains. p-αSyn monomers were decreased and
ubiquitinated p-αSyn dimers with a molecular weight of 45 kDa (arrow) were increased in Tg brains (*p < 0.01, e). In addition to p-αSyn monomers, p-
αSyn dimers (arrowhead) and ubiquitinated p-αSyn dimers (arrow) were detected in the sarkosyl-insoluble fractions of Tg brains (f). One distinct band
of ubiquitin with a molecular weight of 10 kDa was detected in the TBS-soluble fractions of both mouse brains (g), and several bands of ubiquitinated
proteins, including ubiquitinated p-αSyn dimers (arrow), were detected in the sarkosyl-soluble fractions of both mouse brains (h)
Fig. 5 Western blotting analysis of kinases and phosphatase in TBS-soluble fractions from the hindbrain of rTg4510 mice (Tg, n = 10) and control
mice (WT, n = 10). A significant increase was observed in p-GSK-3β (Tyr216) (lower band, arrow, *p < 0.01, b) in Tg brains, whereas no changes
were noted in GSK-3β (a), PLK-2 (c), PP2A (d), and p-PP2A (Tyr307) (e)
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[53]. A30P αSyn transgenic mice develop proteinase K-
resistant LB-like αSyn-positive structures in the neuronal
somata and neurites, predominantly in the brain stem
and spinal cord [37]. In the present study, morphological
differences between proteinase K-resistant αSyn and p-
αSyn deposits suggested that proteinase K-resistant αSyn
was not phosphorylated. Furthermore, the similar re-
gional distribution of hp-tau and proteinase K-resistant
αSyn suggested that αSyn gained proteinase K resistance
in association with hp-tau accumulation.
The oligomeric form of αSyn is considered to play a
central role in the pathogenesis of PD and other α-
synucleinopathies [43]. The phosphorylation of αSyn
leads to oligomerization [21] and is the major underlying
process for the formation of LBs [57]. In the present
study, we detected decreases in p-αSyn monomers in
TBS- and sarkosyl-soluble fractions and increases in ubi-
quitinated p-αSyn dimers in sarkosyl-soluble and insol-
uble fractions in rTg4510 mice. These results suggested
that p-αSyn was more likely to form insoluble oligomers
in the brains of rTg4510 mice. An in vitro study showed
that the co-incubation of tau with αSyn, even at very low
concentrations of tau, resulted in the accumulation of
high-molecular-weight αSyn [15]. Tau oligomers, in
conjunction with αSyn oligomers, enhance their cytotox-
icity and accelerate the formation of αSyn inclusions,
suggesting that toxic protein cross-seeding and
oligomerization are the pathognomic factors involved in
neurodegenerative diseases [4, 22]. αSyn with mutations
of familial PD, such as A53T, A30P, and E46K, show a
faster rate of protein aggregation and greater propensity
to self-interact and form dimeric structures than wild-
type αSyn [44]. Furthermore, αSyn dimers are important
for mature fibril formation because αSyn dimerization
accelerates the formation of neurotoxic intermediate ag-
gregate species and amyloid fibrils [47]. We previously
demonstrated that in addition to p-αSyn-positive grains,
rTg4510 mice developed p-αSyn-positive spherical LB-
like inclusions [51]. Based on these findings, we specu-
late that p-αSyn-positive grains are associated with the
cross-seeding of hp-tau and αSyn, while p-αSyn-positive
spherical LB-like inclusions are also associated with the
self-aggregation of p-αSyn.
Several kinases and phosphatases, including GSK-3β,
PLK2, and PP2A, are associated with the phosphoryl-
ation of tau and α-Syn [10, 27, 35, 55]. In AD, the most
prevalent age-related neurodegenerative disorder, amyl-
oid β has been suggested to induce the activation of
Fig. 6 Immunohistochemistry for GSK-3β in the amygdala of rTg4510 and control mice. The cytoplasmic uniform distribution of GSK-3β was
found in both mice (a, c). GSK-3β-positive grains were found in rTg4510 mice (c). P-GSK-3β (Tyr216)-positive cells were found in rTg4510 mice (d),
but not in control mice (b). Double-labeling immunofluorescence in the hippocampus of rTg4510 mice revealed that p-GSK-3β (Tyr216)-positive
grains were localized in hp-tau-positive cells (e). The majority of p-GSK-3β (Tyr216) grains did not co-localize with hp-tau aggregates (e). P-αSyn-
positive aggregates localized in p-GSK-3β (Tyr216)-positive cells (f). p-αSyn-positive aggregates co-localized with p-GSK-3β (Tyr216)-positive grains
(f). The reactions to hp-tau (e) and p-αSyn (f) are shown in red, and those to p-GSK-3β (Tyr216) (e, f) in green. Scale bars: 20 μm (a-d); 50 μm (e, f)
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GSK-3β by inhibiting Wnt signaling, and the activation
of GSK-3β is closely associated with amyloid β depos-
ition [40, 45]. In the present study, we detected the acti-
vation of GSK-3β in rTg4510 mice fed the control and
doxycycline diets, and a positive correlation was
observed between hp-tau accumulation and GSK-3β ac-
tivation in rTg4510 mice, whereas amyloid β deposits
were absent. Therefore, hp-tau accumulation may have
induced the activation of GSK-3β in rTg4510 mice inde-
pendently from Wnt signaling and amyloid β deposition.
Fig. 7 Semi-quantitative analysis of p-GSK-3β (Tyr216) in 10 regions: hippocampal CA1 and CA3 areas, dentate gyrus (DG), motor area (MO),
somatosensory area (SO), entorhinal cortex (ENT), piriform cortex (PIR), amygdala (AMY), striatum (STR), and substantia nigra (SN), in rTg4510 mice
fed the standard (n = 11) or doxycycline (dox) diet (n = 10). The accumulation of p-GSK-3β (Tyr216) was decreased in all regions studied in
rTg4510 mice fed the dox diet (*p < 0.01, a). Positive correlations were observed between the number of hp-tau-positive cells and p-GSK-3β
(Tyr216)-positive cells (r = 0.91, p < 0.01, b) and between the average number of hp-tau-positive cells and p-GSK-3β (Tyr216)-positive cells in each
region (r = 0.95, p < 0.01, c). Moreover, positive correlations were found between the number of p-αSyn-positive cells and p-GSK-3β (Tyr216)-
positive cells (r = 0.84, p < 0.01, d) and between the average number of p-αSyn-positive cells and p-GSK-3β (Tyr216)-positive cells in each region
(r = 0.93, p < 0.01, e). Colors: red, CA1; purple, CA3; deep red, DG; pink, MO; gray; SO; black, ENT; green; PIR; blue, AMY; light blue, STR; orange, SN.
Diagrams: circular dot, rTg4510 mice fed the control diet; circle, rTg4510 mice fed the dox diet
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The activation of PLK2 and inactivation of PP2A have
been demonstrated in a rat model injected with a lenti-
virus harboring human wild-type or P301L mutant tau
[26]. Moreover, rTg4510 mice show a decrease in PP2A
A subunit levels, a structural subunit, but no changes in
the levels of the PP2A B subunit, a regulatory subunit,
the PP2A C subunit, a catalytic subunit responsible for
enzyme activity, or GSK-3β [36]. In the present study,
we detected an increase in activated GSK-3β levels with
no changes in GSK-3β levels, and no changes in PLK2,
PP2A C subunit, or inactivated PP2A levels in rTg4510
mice. These results suggest that hp-tau accumulation in-
duces the activation of GSK-3β in vivo. The difference in
PLK2 and PP2A activities between rTg4510 mice and
the lentivirus-injected rat model may be due to the ex-
pression levels of hp-tau, the promoter that was used, or
species differences between mice and rats.
In addition to tau, GSK-3β phosphorylates αSyn,
which may enhance αSyn aggregation and neurotoxicity
[57]. In the present study, a positive correlation was ob-
served between GSK-3β activation and p-αSyn accumu-
lation in rTg4510 mice. Previous studies reported that
the overactivation of GSK-3β led to excessive p-αSyn ac-
cumulation in vivo [6, 16]. Furthermore, the up-
regulation of Wnt signaling via the overexpression of β-
catenin or inhibition of GSK-3β was found to protect
PD models from excessive p-αSyn accumulation or the
development of motor deficits [51, 59]. Regarding cross-
seeding, in which the seeds of one protein may induce
the aggregation of another protein, previous studies sug-
gested direct interactions between tau and αSyn [31]. In
rTg4510 mice, the majority of p-αSyn-positive grains
and p-αSyn-positive spherical LB-like inclusions did not
co-localize with hp-tau aggregates [52]. Therefore, we
speculate that in addition to direct interactions between
both proteins, the activation of GSK-3β is of importance
for the accumulation of p-αSyn in rTg4510 mice.
Recent findings support αSyn, directly and via GSK-
3β, promoting tau phosphorylation and aggregation.
αSyn binds to tau via the microtubule-binding region of
tau and serves as a cofactor to promote hp-tau
oligomerization [7, 15, 23]. Furthermore, αSyn oligomers
and protofibrils inhibit the formation of tau-mediated
microtubule assembly, leading to the hyperphosphoryla-
tion and aggregation of tau [41]. The overexpression of
αSyn increases GSK-3β activity and leads to hp-tau ac-
cumulation, and αSyn, hp-tau, and p-GSK-3β (Tyr216)
were found to co-localize in large inclusion bodies [9,
18, 56]. Moreover, A53T and A30P αSyn transgenic
mice and αSyn-injected wild-type mice accumulated hp-
tau in their brains [13, 25, 56]. Therefore, an intracellu-
lar positive feedback loop between hp-tau and p-αSyn
via the promotion of oligomerization with each other
directly and/or through the activation GSK-3β has been
suggested [40]. In the present study, we confirmed that
the overexpression of human P301L mutant tau pro-
moted the activation of GSK-3β, and induced the phos-
phorylation, proteinase K resistance, oligomerization,
insolubilization, and accumulation of endogenous mouse
αSyn. Collectively, previous findings and the present re-
sults indicate that hp-tau and p-αSyn accelerate phos-
phorylation and aggregation with each other via the
activation of GSK-3β and exacerbate the pathology in
rTg4510 mice. These results highlight the importance of
this cellular synergic effect between hp-tau and p-αSyn
in neurodegenerative disorders.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s40478-020-00969-8.
Additional file 1: Supplemental Figure 1. Immunohistochemistry
(IHC) with hp-tau (AT8) and p-αSyn (D1R1R) and without primary anti-
bodies (control) in rTg4510 mice fed the control diet. Hp-tau and p-αSyn-
positive aggregates were found in the hippocampal CA1 (a, b) and CA3
(d, e) areas, motor area (g, h), somatosensory area (j, k), entorhinal cortex
(m, n), piriform cortex (p, q), and striatum (s, t). IHC without a primary
antibody did not detect any deposits in the brain (c, f, i, l, o, r, u). Scale
bar: 20 μm (a-u).
Additional file 2: Supplemental Figure 2. Immunohistochemistry for
αSyn with the proteinase K treatment in rTg4510 mice. rTg4510 mice
developed proteinase K-resistant αSyn in the hippocampus (a), entorhinal
cortex (b), piriform cortex (c), and amygdala (d). Scale bar: 20 μm (a-d).
Additional file 3: Supplemental Figure 3 Immunohistochemistry for
p-GSK-3β (Tyr216) in rTg4510 mice. P-GSK-3β (Tyr216)-positive cells were
found in the hippocampal CA1 (a) and CA3 (b) areas, motor area (c),
somatosensory area (d), entorhinal cortex (e), piriform cortex (f), and stri-
atum (g). Scale bar: 20 μm (a-g).
Additional file 4: Supplementary Figure 4. Western blotting analysis
of TBS-soluble, sarkosyl-soluble, and sarkosyl-insoluble fractions from the
hindbrain of rTg4510 mice (Tg) and control mice (WT) (n = 10 for TBS-
and sarkosyl soluble fractions of Tg and WT mice, n = 3 for sarkosyl insol-
uble fractions of Tg and WT mice). The expression levels of total hp-tau
(AT8) were increased in the TBS- (a) and sarkosyl-soluble (b) and sarkosyl-
insoluble fractions (c) of rTg4510 mice.
Additional file 5: Supplementary Figure 5. Western blotting analysis
of sarkosyl-soluble fractions from the hindbrain of rTg4510 mice (Tg) and
control mice (WT) using anti-p-αSyn antibody 81A (a) and #64 (b). P-αSyn
oligomers including ubiquitinated dimers (arrow) were detected in Tg
and WT mice.
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